SSY Group (HKG:2005) obtained drug production and registration approvals for four products from China's National Medical Products Administration.
The move came as the products passed the regulator's consistency evaluation, according to a Thursday Hong Kong bourse filing.
The drug candidates include Potassium Chloride Injection (Ⅱ) for the treatment of hypokalemia and Metoclopramide Tablets (5mg) for the symptomatic treatment of nausea and vomiting caused by various diseases.
The remaining two approvals are for Sodium Hyaluronate Eye Drops 0.1% for dry eye and 0.3% for corneal and conjunctival epithelial damage.